Cargando…

Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report

RATIONALE: Primary biliary cholangitis (PBC) is a liver autoimmune disease. If this disease is associated with other liver injury factors, both misdiagnosis and missed diagnosis will easily occur. Therefore, detailed disease history collection and related laboratory examination should be performed o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yu, Shao, Chen, Qu, Hao, Zuo, Gang, Jing, Tao, Wan, Taihu, Ji, Shangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156013/
https://www.ncbi.nlm.nih.gov/pubmed/30213010
http://dx.doi.org/10.1097/MD.0000000000012395
_version_ 1783358013096067072
author Sun, Yu
Shao, Chen
Qu, Hao
Zuo, Gang
Jing, Tao
Wan, Taihu
Ji, Shangwei
author_facet Sun, Yu
Shao, Chen
Qu, Hao
Zuo, Gang
Jing, Tao
Wan, Taihu
Ji, Shangwei
author_sort Sun, Yu
collection PubMed
description RATIONALE: Primary biliary cholangitis (PBC) is a liver autoimmune disease. If this disease is associated with other liver injury factors, both misdiagnosis and missed diagnosis will easily occur. Therefore, detailed disease history collection and related laboratory examination should be performed on patients with liver injury for unidentified causes. When necessary, liver biopsy should be performed to confirm the histopathological diagnosis. PATIENT CONCERNS: The subject patient was a 63-year-old Chinese male with chronic liver injury who had a drinking history of about 30 years and drank 500 g daily on average and began to take health products and dietary supplements (multivitamins) since June 2014. DIAGNOSES: Drug-induced liver injury (DILI) and alcoholic fatty liver disease (AFLD) were initially considered because the patient had a history of using health products (HP) and dietary supplements (DS) and drinking alcohol. However, he was subsequently considered with PBC based on the findings of anti-mitochondrial antibody positivity and elevated immunoglobulin level. Obstructive jaundice and space-occupying lesion in the liver were excluded by imaging examinations. Liver biopsy was performed to confirm the reasons for liver injury. Histopathological examination was conducted, and the patient was diagnosed with PBC associated with DILI and alcoholic liver fibrosis. INTERVENTIONS: Ursodeoxycholic acid, glycyrrhizic acid, and methylprednisolone (small dose) were used to treat the patient. OUTCOMES: After 2 months, the serum levels of ALT, AST, AKP, GGT, and globulin returned to normal. After 4 months, the patient showed liver injury once again (an increase in ALT, AST, AKP, GGT and GLB) caused by repaglinide administration due to hyperglycemia. Ursodeoxycholic acid and methylprednisolone replaced the repaglinide administration. After 3 weeks, the levels of ALT, AST, AKP, GGT, and GLB returned to normal again. LESSONS: The correct knowledge on PBC and early-stage recognition and diagnosis should be emphasized. When other causes of the liver injury cannot be excluded, liver biopsy is suggested. Histopathological change can be used to further clarify the reasons for liver injury and the principal contradiction as well as to guide the theraputic regimen.
format Online
Article
Text
id pubmed-6156013
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-61560132018-11-08 Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report Sun, Yu Shao, Chen Qu, Hao Zuo, Gang Jing, Tao Wan, Taihu Ji, Shangwei Medicine (Baltimore) Research Article RATIONALE: Primary biliary cholangitis (PBC) is a liver autoimmune disease. If this disease is associated with other liver injury factors, both misdiagnosis and missed diagnosis will easily occur. Therefore, detailed disease history collection and related laboratory examination should be performed on patients with liver injury for unidentified causes. When necessary, liver biopsy should be performed to confirm the histopathological diagnosis. PATIENT CONCERNS: The subject patient was a 63-year-old Chinese male with chronic liver injury who had a drinking history of about 30 years and drank 500 g daily on average and began to take health products and dietary supplements (multivitamins) since June 2014. DIAGNOSES: Drug-induced liver injury (DILI) and alcoholic fatty liver disease (AFLD) were initially considered because the patient had a history of using health products (HP) and dietary supplements (DS) and drinking alcohol. However, he was subsequently considered with PBC based on the findings of anti-mitochondrial antibody positivity and elevated immunoglobulin level. Obstructive jaundice and space-occupying lesion in the liver were excluded by imaging examinations. Liver biopsy was performed to confirm the reasons for liver injury. Histopathological examination was conducted, and the patient was diagnosed with PBC associated with DILI and alcoholic liver fibrosis. INTERVENTIONS: Ursodeoxycholic acid, glycyrrhizic acid, and methylprednisolone (small dose) were used to treat the patient. OUTCOMES: After 2 months, the serum levels of ALT, AST, AKP, GGT, and globulin returned to normal. After 4 months, the patient showed liver injury once again (an increase in ALT, AST, AKP, GGT and GLB) caused by repaglinide administration due to hyperglycemia. Ursodeoxycholic acid and methylprednisolone replaced the repaglinide administration. After 3 weeks, the levels of ALT, AST, AKP, GGT, and GLB returned to normal again. LESSONS: The correct knowledge on PBC and early-stage recognition and diagnosis should be emphasized. When other causes of the liver injury cannot be excluded, liver biopsy is suggested. Histopathological change can be used to further clarify the reasons for liver injury and the principal contradiction as well as to guide the theraputic regimen. Wolters Kluwer Health 2018-09-14 /pmc/articles/PMC6156013/ /pubmed/30213010 http://dx.doi.org/10.1097/MD.0000000000012395 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Sun, Yu
Shao, Chen
Qu, Hao
Zuo, Gang
Jing, Tao
Wan, Taihu
Ji, Shangwei
Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report
title Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report
title_full Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report
title_fullStr Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report
title_full_unstemmed Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report
title_short Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report
title_sort primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156013/
https://www.ncbi.nlm.nih.gov/pubmed/30213010
http://dx.doi.org/10.1097/MD.0000000000012395
work_keys_str_mv AT sunyu primarybiliarycholangitisassociatedwithdruginducedliverinjuryandalcoholicliverfibrosisacasereport
AT shaochen primarybiliarycholangitisassociatedwithdruginducedliverinjuryandalcoholicliverfibrosisacasereport
AT quhao primarybiliarycholangitisassociatedwithdruginducedliverinjuryandalcoholicliverfibrosisacasereport
AT zuogang primarybiliarycholangitisassociatedwithdruginducedliverinjuryandalcoholicliverfibrosisacasereport
AT jingtao primarybiliarycholangitisassociatedwithdruginducedliverinjuryandalcoholicliverfibrosisacasereport
AT wantaihu primarybiliarycholangitisassociatedwithdruginducedliverinjuryandalcoholicliverfibrosisacasereport
AT jishangwei primarybiliarycholangitisassociatedwithdruginducedliverinjuryandalcoholicliverfibrosisacasereport